Brown Brothers Harriman & CO Syndax Pharmaceuticals Inc Transaction History
Brown Brothers Harriman & CO
- $14.8 Billion
- Q2 2025
A detailed history of Brown Brothers Harriman & CO transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 128 shares of SNDX stock, worth $1,713. This represents 0.0% of its overall portfolio holdings.
Number of Shares
128Holding current value
$1,713% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SNDX
# of Institutions
252Shares Held
100MCall Options Held
1.28MPut Options Held
1.29M-
Kynam Capital Management, LP Princeton, NJ8.52MShares$114 Million9.53% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$106 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.8MShares$77.6 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$67.4 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.07MShares$54.4 Million3.84% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $757M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...